TXNIP/NLRP3 inflammasome pathway-associated proteins are abnormally expressed in the SN of T2DM rats, and inhibiting the activation of this pathway can alleviate DNP-related symptoms, so TXNIP/NLRP3 inflammasome pathway can be considered as a therapeutic target for DNP. This evidence concerns the gene TXNIP and type 2 diabetes mellitus.